There are many types of arthritis, over 100 types to be exact. While they all…
The FDA has approved Spravato (esketamine), the first new kind of antidepressant in decades, for treatment-resistant depression. The approval follows…
An FDA advisory committee overwhelmingly voted in favor of approving esketamine, which is related to the party drug ketamine, as…
With many people suffering from depression not responding to antidepressants despite trying several, there is a critical need for therapies…
The FDA has fast-tracked for potential approval a derivative of the party drug ketamine for major depression. The drug, esketamine,…
MedShadow Foundation is an independent nonprofit health & wellness journalism organization focused on helping to protect lives from the side effects of medication and lower risk with alternative health options.
We help protect your life and the lives of your family by making sure you have the information you need to make informed decisions about the risks, benefits and alternatives to medicines.
Even though MedShadow is nonprofit, we refuse to accept support from pharmaceutical companies or medical device manufacturers. You can be sure that our information is free from the influence of pharmaceutical companies.
Symptoms & Concerns
MedShadow Foundation does not provide medical advice, diagnosis or treatment.
This site complies with the HONcode standard for trustworthy health information.
MedShadow Foundation is a registered 501(c)(3) non-profit organization. MedShadow does not accept advertising or contributions from pharmaceutical companies, medical device manufacturers or political action organizations.
Copyright © 2022, MedShadow Foundation. all rights reserved. Designed by Dante Steward